Intra-Cellular Therapies (ITCI) - News Mentions

Sign up to add (ITCI) to your portfolio and access more historical data.

00%
Est. daily news mentions.

Sign up to access historical data

Sign up

Similar companies

Company News Mentions
Amgen
Amgen
AMGN		 1 0%
Gilead Sciences
Gilead Sciences
GILD		 1 50%
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
CPRX		 0 0%
Inovio Pharmaceuticals
Inovio Pharmaceuticals
INO		 0 0%
Anavex Life Sciences
Anavex Life Sciences
AVXL		 0 100%
Connor Clark & Lunn Investment Management Ltd. Invests $1.25 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 27
Commerce Bank Cuts Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 27
B. Metzler seel. Sohn & Co. Holding AG Takes $2.44 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 22
KBC Group NV Acquires 423 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 21
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
November 19
Entropy Technologies LP Invests $521,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 16
Covestor Ltd Increases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 12
M&G Plc Acquires New Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 9
Wealth Enhancement Advisory Services LLC Grows Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 8
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
November 6
Intra-Cellular Therapies (NASDAQ:ITCI) Hits New 52-Week High Following Analyst Upgrade
November 5
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
November 5
FY2024 Earnings Estimate for ITCI Issued By Leerink Partnrs
November 4
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
November 4
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $96.62 Average Target Price from Brokerages
November 2
Pallas Capital Advisors LLC Sells 1,130 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
November 2

Month over Month

Est. daily news mentions.

Oct 2024 0
Sep 2024 0
Aug 2024 0
Jul 2024 0

How often is Intra-Cellular Therapies mentioned in the news?

Intra-Cellular Therapies was mentioned an estimated 0 times in online prominent news articles yesterday.

Analyzing News Mentions, how is Intra-Cellular Therapies performing compared to its industry peers?

Intra-Cellular Therapies underperforms its industry peers when it comes to News Mentions, ranking dead last.

Has there been an increase or decrease in news mentions of Intra-Cellular Therapies in the last month?

There has been no significant change in the number of news mentions for Intra-Cellular Therapies' compared to the last month.

Why is it important to track news mentions for Intra-Cellular Therapies?

By monitoring mentions in the news for Intra-Cellular Therapies, investors stay up to date on impactful events for the company, its industry and its competitors. Positive news might affect price in a positive way and negative news might affect price in a negative way. By tracking mentions over time, investors can also identify patterns, explore popularity and make informed decisions based on the evolving perception of Intra-Cellular Therapies, ultimately improving their investment strategies.

Sign up and get more insights on Intra-Cellular Therapies.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.

Top Stocks

Trending Stocks
Trending Stocks on WallStreetBets
Trending Stocks on Reddit
Top Stocks
Top Stock Performers Today
Bottom Stock Performers Today
Best Airlines Stocks
Best Bank Stocks
Best Semiconductor Stocks
Best Energy Stocks
Best Fintech Stocks
Best Robotics Stocks
Best Insurance Stocks

Our Data

Datasets
Stock alerts
AI Stock Picks
AI Stock Picks - Results
Fear & Greed Index
Meme Stocks
Threads Users
Stock Predictor
Stock Picking Reviews
Stock Trading Signals
House & Congress Trading
Earnings Calendar
Index

AltIndex

News
Pricing
Sign up
Log in
API
Journalist Access
Data Disclaimer
Contact